|Day's Range||23.75 - 23.75|
People reveal more personal and intimate details to human-like apps and bots that can ‘sense’ emotions and concerns.
Moody's Investors Service ("Moody's") assigned a Baa1 rating to the new senior unsecured note offering of Amgen Inc. ("Amgen"). There are no changes to the existing ratings of Amgen including the Baa1 senior unsecured long-term rating and the Prime-2 short-term rating. Amgen's Baa1 rating reflects its position as the largest stand-alone biotechnology company, its high margins and its good cash flow.
John Buckingham is a value-oriented money manager and editor of the industry-leading advisory service, The Prudent Speculator. Here he reviews two recommended healthcare stocks -- both large cap players in the biotechnology sector.
In a note out Thursday evening, Citi Research analyst Mohit Bansal put his money on (VRTX) the up-and-comer that analysts can’t say enough good things about. “VRTX could be the next entry in the $100B market cap club,” Bansal wrote. (VRTX) (ticker: VRTX) tops Bansal’s ranking of large-cap biotech names, a list that includes (AMGN)(AMGN), (REGN)(REGN), (GILD)(GILD), and (BIIB)(BIIB), among others.
The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse. The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc.
The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc. China has imposed a virtual lockdown on Wuhan and severely restricted travel in its wider province of Hubei and some other cities.
J&J (JNJ) seeks approval for new Darzalex combo regimen in the United States to treat relapsed/refractory multiple myeloma patients who have received one to three prior lines of therapy.
The main point of investing for the long term is to make money. Furthermore, you'd generally like to see the share...
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Amgen saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 79 to 84. For the period ended Dec. 31, Amgen earned $3.64 per share, minus some items, on $6.2 billion in sales. Chief Executive Robert Bradway said in the earnings release that the company is entering what he called a new product-driven revenue era.
Shares of the pharmaceutical companies firm Bristol-Myers Squibb jumped 3% in premarket trading early Thursday after the company announced financial results for the last quarter of 2019 that blew past analyst expectations.
Survivors in Canada are Taking Steps to Reduce the Risk of Another Heart Attack. But is it Enough?
Amgen stock is facing concerns that its adjusted earnings will slide in 2020. Is it time to buy shares of the biotech company?